Synmosa Board of Directors resolved to buy back
Synmosa common stocks
Date of events
2022/03/29
To which item it meets
paragraph 35
Statement
1.Date of the board of directors resolution:2022/03/29
2.Purpose of the share repurchase:4,000,000 shares
3.Type of shares to be repurchased:Common stocks
4.Ceiling on total monetary amount of share repurchase (NTD):1,177,467,300
5.Scheduled period for the repurchase:2022/3/30~2022/5/29
6.No.of shares to be repurchased (shares):4,000,000 shares
7.Repurchase price range (NTD):NT$17.5 per share to NT$36.5 per share
8.Method for the repurchase:
To buy back shares at a centralized securities exchange market
9.Shares to be repurchased as a percentage of total
issued shares of the company (%):
1.28%
10.Cumulative no.of the company's own shares held
at the time of reporting (shares):
13,519,000 shares
11.Status of repurchases within three years prior to
the time of reporting:None
12.Status of repurchases that have been reported but
not yet completed:
The last (thirteenth) execution rate was 100%
13.Minutes of the board of directors meeting that resolved
for the share repurchase:NA
14.The Rules for Transfer of Shares set forth in Article
10 of the Regulations Governing Share Repurchase by
TWSE-listed and TPEx-Listed Companies:NA
15.The Rules for Conversion of Shares or the Rules for
Subscription of Shares set forth in Article 11 of the
Regulations Governing Share Repurchase by TWSE-listed
and TPEx-Listed Companies:NA
16.Declaration that the financial status of the company
has been considered by the board of directors, and that
its capital maintenance will not be affected:NA
17.Appraisal or opinion by a CPA or securities underwriter
about the reasonableness of the share repurchase price:NA
18.Any other matters stipulated by the SFB:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Synmosa Biopharma Corporation published this content on 29 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 March 2022 08:03:07 UTC.
SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.
SYNMOSA BIOPHARMA CORPORATION 
